Earlier today, Asarina Pharma announced the full enrolment in its phase 2a study in menstrual migraine (MM). 158 women have been enrolled in this first-in-man proof-of-concept study in MM with sepranolone. The primary endpoint is change in migraine days measured before and during three treatment cycles. We are encouraged by the full enrolment, which follows the timeline. Per the company’s communication, we expect top-line results in Q2’21.